Gregory Hawkins

Dr. Gregory Hawkins


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MOMichael Olivier
Michael Olivier
Reto AsmisReto Asmis
Reto Asmis
GHGregory Hawkins
Gregory Hawkins
THTimothy D. Howard
Timothy D. Howard
Laura A. CoxLaura A. Cox
Laura A. Cox
Recent advances in omics technologies have led to unprecedented efforts characterizing the molecular changes that underlie the development and progression of a wide array of complex human diseases, including cancer. As a result, multi-omics analyses—which take advantage of these technologies in genomics, transcriptomics, epigenomics, proteomics, metabolomics, and other omics areas—have been proposed and heralded as the key to advancing precision medicine in the clinic. In the field of precision oncology, genomics approaches, and, more recently, other omics analyses have helped reveal several key mechanisms in cancer development, treatment resistance, and recurrence risk, and several of these findings have been implemented in clinical oncology to help guide treatment decisions. However, truly integrated multi-omics analyses have not been applied widely, preventing further advances in precision medicine. Additional efforts are needed to develop the analytical infrastructure necessary to generate, analyze, and annotate multi-omics data effectively to inform precision medicine-based decision-making.

1 August 2012 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
GHGregory Hawkins
Gregory Hawkins
MRMac B. Robinson
Mac B. Robinson
AHAnnette T. Hastie
Annette T. Hastie
XLXingnan Li
Xingnan Li
HLHuashi Li
Huashi Li
EBEugene R. Bleecker
Eugene R. Bleecker

15 July 2015 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
MRMac B. Robinson
Mac B. Robinson
DDDeepak A. Deshpande
Deepak A. Deshpande
JCJeffery Chou
Jeffery Chou
WCWei Cui
Wei Cui
SSShelly Smith
Shelly Smith
GHGregory Hawkins
Gregory Hawkins
Genetic data suggest that IL-6 trans-signaling may have a pathogenic role in the lung; however, the effects of IL-6 trans-signaling on lung effector cells have not been investigated. In this study, human airway smooth muscle (HASM) cells were treated with IL-6 (classical) or IL-6+sIL6R (trans-signaling) for 24 h and gene expression was measured by RNAseq. Intracellular signaling and transcription factor activation were assessed by Western blotting and luciferase assay, respectively. The functional effect of IL-6 trans-signaling was determined by proliferation assay. IL-6 trans-signaling had no effect on phosphoinositide-3 kinase and Erk MAP kinase pathways in HASM cells. Both classical and IL-6 trans-signaling in HASM involves activation of Stat3. However, the kinetics of Stat3 phosphorylation by IL-6 trans-signaling was different than classical IL-6 signaling. This was further reflected in the differential gene expression profile by IL-6 trans-signaling in HASM cells. Under IL-6 trans-signaling conditions 36 genes were upregulated, including PLA2G2A, IL13RA1, MUC1, and SOD2. Four genes, including CCL11, were downregulated at least twofold. The expression of 112 genes was divergent between IL-6 classical and trans-signaling, including the genes HILPDA, NNMT, DAB2, MUC1, WWC1, and VEGFA. Pathway analysis revealed that IL-6 trans-signaling induced expression of genes involved in regulation of airway remodeling, immune response, hypoxia, and glucose metabolism. Treatment of HASM cells with IL-6+sIL6R induced proliferation in a dose-dependent fashion, suggesting a role for IL-6 trans-signaling in asthma pathogenesis. These novel findings demonstrate differential effect of IL-6 trans-signaling on airway cells and identify IL-6 trans-signaling as a potential modifier of airway inflammation and remodeling.

1 August 2018 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
FGfor the SPIROMICS Research Group
for the SPIROMICS Research Group
XLXingnan Li
Xingnan Li
VOVictor E. Ortega
Victor E. Ortega
EAElizabeth J. Ampleford
Elizabeth J. Ampleford
RBR. Graham Barr
R. Graham Barr
DMDeborah A. Meyers
Deborah A. Meyers
The aim of this study is to identify genetic loci associated with post-bronchodilator FEV1/FVC and FEV1, and develop a multi-gene predictive model for lung function in COPD. Genome-wide association study (GWAS) of post-bronchodilator FEV1/FVC and FEV1 was performed in 1645 non-Hispanic White European descent smokers. A functional rare variant in SERPINA1 (rs28929474: Glu342Lys) was significantly associated with post-bronchodilator FEV1/FVC (p = 1.2 × 10− 8) and FEV1 (p = 2.1 × 10− 9). In addition, this variant was associated with COPD (OR = 2.3; p = 7.8 × 10− 4) and severity (OR = 4.1; p = 0.0036). Heterozygous subjects (CT genotype) had significantly lower lung function and higher percentage of COPD and more severe COPD than subjects with the CC genotype. 8.6% of the variance of post-bronchodilator FEV1/FVC can be explained by SNPs in 10 genes with age, sex, and pack-years of cigarette smoking (P < 2.2 × 10− 16). This study is the first to show genome-wide significant association of rs28929474 in SERPINA1 with lung function. Of clinical importance, heterozygotes of rs28929474 (4.7% of subjects) have significantly reduced pulmonary function, demonstrating a major impact in smokers. The multi-gene model is significantly associated with CT-based emphysema and clinical outcome measures of severity. Combining genetic information with demographic and environmental factors will further increase the predictive power for assessing reduced lung function and COPD severity.

1 September 2012 in Clinics in Chest Medicine
Verified
Journal Article
Closed access
RSRebecca E. Slager
Rebecca E. Slager
GHGregory Hawkins
Gregory Hawkins
XLXingnan Li
Xingnan Li
DPDirkje S. Postma
Dirkje S. Postma
DMDeborah A. Meyers
Deborah A. Meyers
EBEugene R. Bleecker
Eugene R. Bleecker

31 December 2016 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
JCJames B. Caress
James B. Caress
JJJanel O. Johnson
Janel O. Johnson
YAYevgeniya A. Abramzon
Yevgeniya A. Abramzon
GHGregory Hawkins
Gregory Hawkins
JGJ. Raphael Gibbs
J. Raphael Gibbs
BTBryan J. Traynor
Bryan J. Traynor